Author

T. C. Smith

Primary ORCID profile (0009-0004-9955-4915 · 5 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

T. C. SmithiD5 papers · Pennsylvania State University

Biology Disciplines

Click to filter author papers

Microbiology· 3 Ecology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Organism:bacteria (other)· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

B. B. Aldridge· 2 shared J. Larkins-Ford· 2 shared M. B. Joseph· 2 shared R. A. Knapp· 2 shared A. B. Cognetta· 1 shared A. J. Jani· 1 shared A. P. Rothstein· 1 shared A. Q. Byrne· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. B. Aldridge

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Reintroduction of resistant frogs facilitates landscape-scale recovery in the presence of a lethal fungal disease

R. A. Knapp, M. Q. Wilber, A. Q. Byrne, M. B. Joseph, T. C. Smith, A. P. Rothstein, R. L. Grasso, E. B. Rosenblum

This study shows reintroducing Bd-resistant frogs can recover populations despite the disease, with genetic evidence of evolutionary resistance.

bioRxiv · May 22, 2023Ecology

Novel synergies and isolate specificities in the drug interactions landscape of Mycobacterium abscessus

N. Van, Y. N. Degefu, P. A. Leus, J. Larkins-Ford, J. Klickstein, F. P. Maurer, D. Stone, H. Poonawala, C. M. Thorpe, T. C. Smith, B. B. Aldridge

This study systematically measures drug interactions in Mycobacterium abscessus to identify synergistic combinations and highlight strain-specific responses.

bioRxiv · Dec 12, 2022Microbiology

Effectiveness of antifungal treatments during chytridiomycosis epizootics in populations of an endangered frog

R. A. Knapp, M. B. Joseph, T. C. Smith, E. E. Hegeman, V. T. Vredenburg, J. E. Erdman, D. M. Boiano, A. J. Jani, C. J. Briggs

This study evaluates antifungal treatments for chytridiomycosis in frogs, finding that while treatments reduce Bd load temporarily, they fail to ensure long-term population persistence.

bioRxiv · Jun 13, 2021Ecology

A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis

M. Li, H. V. Patel, A. B. Cognetta, T. C. Smith, B. B. Aldridge, I. Mallick, J.-F. Cavalier, T. C. Smith, B. F. Cravatt, J. C. Seeliger

This study uses ABPP to identify cell wall synthesis inhibitors targeting Mycobacterium tuberculosis, showing that active compounds inhibit serine hydrolases involved in cell wall and lipid metabolism.

bioRxiv · Apr 16, 2021Microbiology

Morphological profiling of tubercule bacilli identifies drug pathways of action

T. C. Smith, K. M. Pullen, M. C. Olson, M. E. McNellis, I. Richardson, S. Hu, J. Larkins-Ford, X. Wang, J. S. Freundlich, D. M. Ando, B. Aldridge

This paper introduces MorphEUS, a morphological profiling method that classifies drugs based on their effects on Mycobacterium tuberculosis morphology, identifying both primary and off-target pathways of action.

bioRxiv · Mar 11, 2020Microbiology